318 related articles for article (PubMed ID: 31168764)
1. Inosine Pranobex: A Key Player in the Game Against a Wide Range of Viral Infections and Non-Infectious Diseases.
Sliva J; Pantzartzi CN; Votava M
Adv Ther; 2019 Aug; 36(8):1878-1905. PubMed ID: 31168764
[TBL] [Abstract][Full Text] [Related]
2. Inosine Pranobex Deserves Attention as a Potential Immunomodulator to Achieve Early Alteration of the COVID-19 Disease Course.
Beran J; Špajdel M; Slíva J
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835052
[TBL] [Abstract][Full Text] [Related]
3. Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
Campoli-Richards DM; Sorkin EM; Heel RC
Drugs; 1986 Nov; 32(5):383-424. PubMed ID: 2431857
[TBL] [Abstract][Full Text] [Related]
4. Inosine pranobex is safe and effective for the treatment of subjects with confirmed acute respiratory viral infections: analysis and subgroup analysis from a Phase 4, randomised, placebo-controlled, double-blind study.
Beran J; Šalapová E; Špajdel M;
BMC Infect Dis; 2016 Nov; 16(1):648. PubMed ID: 27821093
[TBL] [Abstract][Full Text] [Related]
5. The immunomodulatory action of inosiplex in relation to its effects in experimental viral infections.
Ohnishi H; Kosuzume H; Inaba H; Ohkura M; Shimada S; Suzuki Y
Int J Immunopharmacol; 1983; 5(3):181-96. PubMed ID: 6194125
[TBL] [Abstract][Full Text] [Related]
6. [Immunological and clinical study on therapeutic efficacy of inosine pranobex].
Gołebiowska-Wawrzyniak M; Markiewicz K; Kozar A; Derentowicz P; Czerwińska-Kartowicz I; Jastrzebska-Janas K; Wacławek J; Wawrzyniak ZM; Siwińska-Gołebiowska H
Pol Merkur Lekarski; 2005 Sep; 19(111):379-82. PubMed ID: 16358878
[TBL] [Abstract][Full Text] [Related]
7. Isoprinosine: an overview.
Simon LN; Glasky AJ
Cancer Treat Rep; 1978 Nov; 62(11):1963-9. PubMed ID: 83189
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory activity of isoprinosine on experimental viral infections in avian models.
Moya P; Alonso ML; Baixeras E; Ronda E
Int J Immunopharmacol; 1984; 6(4):339-43. PubMed ID: 6207123
[TBL] [Abstract][Full Text] [Related]
9. Comparative studies of inosine pranobex and acyclovir.
Mindel A
Am J Med; 1988 Aug; 85(2A):7-9. PubMed ID: 2457315
[TBL] [Abstract][Full Text] [Related]
10. [Concepts of stimulating immunotherapy].
Aiuti F; Montella F
Minerva Med; 1982 Apr; 73(15):895-8. PubMed ID: 6176915
[No Abstract] [Full Text] [Related]
11. Immunomodulatory effects of inosine pranobex on cytokine production by human lymphocytes.
Lasek W; Janyst M; Wolny R; Zapała Ł; Bocian K; Drela N
Acta Pharm; 2015 Jun; 65(2):171-80. PubMed ID: 26011933
[TBL] [Abstract][Full Text] [Related]
12. A recent overview on in vitro and in vivo immunological activities of methisoprinol.
Morin A; Ballet JJ
Allergol Immunopathol (Madr); 1982; 10(2):109-14. PubMed ID: 6179407
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic experiences with the immunostimulator inosine pranobex].
Darlath W; Wybran J
Fortschr Med; 1984 Oct; 102(37):932-4. PubMed ID: 6209193
[TBL] [Abstract][Full Text] [Related]
14. An assessment of antiviral drugs for the management of infectious diseases in humans.
Galasso GJ
Antiviral Res; 1981 Jun; 1(2):73-96. PubMed ID: 6175275
[No Abstract] [Full Text] [Related]
15. Clinical and immunological assessment in HIV+ subjects receiving inosine-pranobex. A randomised, multicentric study.
De Simone C; Albertini F; Almaviva M; Angarano G; Chiodo F; Costigliola P; Delia S; Ferlini A; Gritti F; Mazzarello G
Med Oncol Tumor Pharmacother; 1989; 6(1):63-7. PubMed ID: 2471025
[TBL] [Abstract][Full Text] [Related]
16. [Inosine pranobex - cytotoxic activities and effect of on replication of human parainfluenza viruses (HPIV-2, HPIV-4), entroviruses (CA16, EV71) and adenoviruses (HAdV-2, HAdV-5) in vitro].
Majewska A; Lasek W; Młynarczyk G
Med Dosw Mikrobiol; 2015; 67(2):107-13. PubMed ID: 26591662
[TBL] [Abstract][Full Text] [Related]
17. Inosine pranobex--only for use in controlled trials.
Drug Ther Bull; 1986 Dec; 24(24):95-6. PubMed ID: 2433117
[No Abstract] [Full Text] [Related]
18. The efficacy of inosine pranobex in preventing the acquired immunodeficiency syndrome in patients with human immunodeficiency virus infection. The Scandinavian Isoprinosine Study Group.
Pedersen C; Sandström E; Petersen CS; Norkrans G; Gerstoft J; Karlsson A; Christensen KC; Håkansson C; Pehrson PO; Nielsen JO
N Engl J Med; 1990 Jun; 322(25):1757-63. PubMed ID: 1693173
[TBL] [Abstract][Full Text] [Related]
19. [Isoprinosine--antiviral drug with immunostimulating properties].
Kowalski J
Pol Tyg Lek; 1989 Aug 21-28; 44(34-35):795-7. PubMed ID: 2484733
[No Abstract] [Full Text] [Related]
20. Modulation of human T lymphocyte functions by isoprinosine.
Rey A; Cupissol D; Thierry C; Esteve C; Serrou B
Int J Immunopharmacol; 1983; 5(1):99-103. PubMed ID: 6188707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
